Wang Xia, Gregory-Evans Cheryl Y
Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, V5Z 3N9, Canada,
Cell Mol Life Sci. 2015 May;72(10):1931-8. doi: 10.1007/s00018-015-1843-0. Epub 2015 Feb 5.
Premature termination codons (PTCs) are caused by nonsense mutations and this leads to either degradation of the mutant mRNA template by nonsense-mediated decay (NMD) or the production of a non-functional, truncated polypeptide. PTCs contribute significantly to inherited human diseases including ocular disorders. Nonsense suppression therapy allows readthrough of PTCs, thereby rescuing the production of a full-length functional protein. In this review, we highlight the mechanisms that are involved in discriminating normal translation termination from premature termination codons; the current understanding of nonsense-mediated mRNA decay models (NMD); the association and crosstalk between PTC and the underlying dynamic NMD process; and the suppression therapies that have been employed in nonsense-medicated ocular disease models. Defining the mechanistic complexity of PTC and NMD will be important to improve treatments of the numerous genetic disorders caused by PTC mutations.
提前终止密码子(PTC)由无义突变引起,这会导致突变的mRNA模板通过无义介导的衰变(NMD)降解,或者产生无功能的截短多肽。PTC在包括眼部疾病在内的遗传性人类疾病中起重要作用。无义抑制疗法允许PTC通读,从而挽救全长功能蛋白的产生。在本综述中,我们重点介绍了区分正常翻译终止与提前终止密码子所涉及的机制;目前对无义介导的mRNA衰变模型(NMD)的理解;PTC与潜在的动态NMD过程之间的关联和相互作用;以及在无义介导的眼部疾病模型中采用的抑制疗法。明确PTC和NMD的机制复杂性对于改善由PTC突变引起的众多遗传疾病的治疗至关重要。